304 related articles for article (PubMed ID: 32326341)
1. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer.
Regel I; Mayerle J; Mahajan UM
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326341
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer subtypes: a roadmap for precision medicine.
Torres C; Grippo PJ
Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
[TBL] [Abstract][Full Text] [Related]
3. Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma.
Roy S; Singh AP; Gupta D
Heliyon; 2021 Jan; 7(1):e06000. PubMed ID: 33521362
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.
Frappart PO; Hofmann TG
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987786
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.
Giannis D; Moris D; Barbas AS
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802340
[TBL] [Abstract][Full Text] [Related]
6. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer.
Khomiak A; Brunner M; Kordes M; Lindblad S; Miksch RC; Öhlund D; Regel I
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33147766
[TBL] [Abstract][Full Text] [Related]
7. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
8. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
9. Preclinical models derived from endoscopic ultrasound-guided tissue acquisition for individualized treatment of pancreatic ductal adenocarcinoma.
Tong T; Zhang C; Li J; Deng M; Wang X
Front Med (Lausanne); 2022; 9():934974. PubMed ID: 36687406
[TBL] [Abstract][Full Text] [Related]
10. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
Manji GA; Olive KP; Saenger YM; Oberstein P
Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
[TBL] [Abstract][Full Text] [Related]
11. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer actionable genes in precision medicine and personalized surgery.
Yu J; Liu SH; Sanchez R; Nemunaitis J; Rozengurt E; Brunicardi FC
Surgeon; 2017 Feb; 15(1):24-29. PubMed ID: 27374183
[TBL] [Abstract][Full Text] [Related]
13. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?
Sereti E; Karagianellou T; Kotsoni I; Magouliotis D; Kamposioras K; Ulukaya E; Sakellaridis N; Zacharoulis D; Dimas K
J Proteomics; 2018 Sep; 188():107-118. PubMed ID: 29398619
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.
Hegde S
Indian J Surg Oncol; 2021 Apr; 12(Suppl 1):118-127. PubMed ID: 33994737
[TBL] [Abstract][Full Text] [Related]
15. Integrin-based therapy of pancreatic adenocarcinoma: current status and future perspectives.
Oron Y
Minerva Gastroenterol Dietol; 2015 Jun; 61(2):71-86. PubMed ID: 25610998
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
17. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?
Kokkinos J; Jensen A; Sharbeen G; McCarroll JA; Goldstein D; Haghighi KS; Phillips PA
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067833
[TBL] [Abstract][Full Text] [Related]
18. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease.
Popp FC; Popp MC; Zhao Y; Betzler C; Kropf S; Garlipp B; Benckert C; Kalinski T; Lippert H; Bruns CJ
BMC Cancer; 2017 Mar; 17(1):229. PubMed ID: 28356064
[TBL] [Abstract][Full Text] [Related]
19. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
